Nuwellis Inc (22SA.BE)
Chart Events
Performance Outlook
| Previous Close | 7.52 |
| Open | 7.36 |
| Bid | 6.78 x N/A |
| Ask | 7.04 x N/A |
| Day's Range | 6.84 - 7.38 |
| 52 Week Range | 6.28 - 161.00 |
| Volume | |
| Avg. Volume | 34 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for 22SA.BE
Related Research
- GlobeNewswire
Nuwellis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results
MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be approximately $2.3 million and $8.5 million, respectively, representing an increase of 42% and 8% over the same periods
- GlobeNewswire
Nuwellis Appoints Dr. John Jefferies as Chief Medical Officer
Dr. Jefferies brings over two decades of cardiology and heart failure expertise to Nuwellis as the Company expands clinical evidence supporting the use of ultrafiltration for people with fluid overloadMINNEAPOLIS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of John Jefferies, MD, MPH, FACC, FHFSA as Chief Medical Officer (CMO). In this new role, Dr. J
- GlobeNewswire
Nuwellis, Inc. Announces Passage of Warrant Proposal
MINNEAPOLIS, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that the Company held its adjourned special meeting of stockholders on January 4, 2023 at 2:00 p.m. (Central Time) (the “Special Meeting”). At the time of the Special Meeting, stockholders (i) approved the Warrant Proposal (as defined below) and (ii) authorized one or more adjournments of the meeting of stockho
